Drug reference

inamrinone

PDE3 inhibitor (positive inotrope / vasodilator) · inotropic agent

START

Load 0.75 mg/kg IV slow, then 5–10 mcg/kg/min infusion

TYPICAL MAX

10 mg/kg/24 h

STOP IF

Severe thrombocytopenia, ventricular arrhythmia, or severe hypotension

WATCH

ECG, BP/CO, platelets, LFTs; short-term use only

CDSCO approvedATC C01CE01

Dose laddermg/d

Renal dose adjustmenteGFR mL/min/1.73m²

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours

ONSET: 3min · IV onset
PEAK: 12min · steady state
t½: 3.6h · t½
DURATION: 1h · post-stop

EXCRETION

Renal — mainly metabolites

route + CYP

INTERACTIONS

1 major

SEVERE in our sources

PREGNANCY

Use only if benefit outweighs risk; limited data.

FDA category + note

Top interactionssee all 5 →

Other Pde3 InhibitorsSevereDatabaseKimi deep-research + Cla

Mechanism

Inhibits cardiac and vascular phosphodiesterase-3, raising intracellular cAMP — increases myocardial contractility (positive inotropy) and produces vasodilation (afterload/preload reduction); inodilator profile useful in heart failure.

Indications

Short-term IV management of severe heart failure unresponsive to other therapy

Dosing

Adult: Loading 0.75 mg/kg IV slowly over 2–3 min, then maintenance 5–10 mcg/kg/min IV infusion; max ~10 mg/kg/24 h.
Pediatric: Specialist (neonates/infants weight-based).
Renal adjustment: Caution; reduce infusion rate / extend interval in severe impairment.
Hepatic adjustment: Caution in significant impairment.
Geriatric: Standard ICU titration; monitor BP/arrhythmias.
Max dose: 10 mg/kg/24 h

Pharmacokinetics

Onset

Within 2–5 min (IV)

Peak effect

~10 min (steady-state infusion)

Duration

30–60 min after stopping infusion

Half-life

~3.6 h (longer in heart failure / renal failure)

Bioavailability

IV 100%

Protein binding

~10–49%

Metabolism

Hepatic

Excretion

Renal (mainly metabolites)

Contraindications

Hypersensitivity to bisulfites (formulation contains sodium metabisulphite)
Severe aortic / pulmonic valvular disease (caution)
Acute MI in some scenarios

Side effects

Common

Thrombocytopenia (especially prolonged use)ArrhythmiaHypotensionNausea/vomitingHeadache

Serious

Severe thrombocytopenia
Ventricular arrhythmias
Severe hypotension
Hepatotoxicity (prolonged use)
Anaphylactoid reactions

Pregnancy & lactation

Pregnancy

Use only if benefit outweighs risk; limited data.

Lactation

Limited data; avoid.

Drug interactions

Other Pde3 Inhibitors

Severe

Database

Duplicate therapy

Do not combine